Navigation Links
Dr. Neal Rouzier Joins BioTE Medical
Date:7/22/2014

DALLAS, July 22, 2014 /PRNewswire/ -- BioTE Medical, a leading provider of hormone replacement therapy using natural, bio-identical hormone pellets, today announced the addition of Dr. Neal Rouzier, MD to the company.   Dr. Rouzier is joining the BioTE Medical Advisory Board as a training physician.     

Dr. Rouzier was residency trained in Family Medicine and Emergency Medicine at UCLA and is a board certified emergency physician still practicing at a large metropolitan trauma center in Southern California.  He is also founder and director of the Preventive Medicine Clinic of Palm Springs where he specializes in optimizing hormones for men and women.  Commenting on the addition of Dr. Rouzier to the BioTE Medical team, BioTE Medical Founder Dr. Gary Donovitz commented, "I've known Dr. Neal Rouzier for years.   His dedication to innovation in the areas of anti-aging and hormone replacement therapy make him a perfect fit with BioTE Medical.  Our growth has been phenomenal in the last 3 years, and with the leadership of people like Dr. Rouzier, we're going to be helping more and more people discover how good life can be when their hormones are balanced."     

Dr. Rouzier stated that he was looking forward to making a contribution to the fast growing BioTE Medical and that he shares Dr. Donovitz's passion for teaching.   He said, "Dr. Donovitz, Dan DeNeui (BioTE COO) and their team have done tremendous work to bring bio-identical hormone replacement to the forefront of people's awareness.   I'm looking forward to helping the
'/>"/>

SOURCE BioTE Medical
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Robert Farrell Joins Bionovos Board of Directors
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. First Choice Rehabilitation Specialists Joins Select Medical
6. Excel Life Sciences Joins DATATRAKs Connect Partner Program
7. Marina Biotech, Inc. Joins OTCQX
8. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
9. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Working in collaboration with the National Amyloidosis ... , Richmond Pharmacology is the first centre worldwide to ... an investigational RNAi therapeutic being developed for the treatment of ... heart. Read press release ... St Georges University of London , Richmond ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... N.J., March 26, 2015  Roka Bioscience, Inc. ... focused on providing advanced testing solutions for the ... results for the three months and full year ... 2014 Financial Results:Revenue for the quarter ended December ... for the fourth quarter of 2013 and $1.5 ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics ... announced that after dealing with certain matters, including the ... shareholders held on March 26, 2015 (the "Meeting") was ... April 8, 2015 at 11:00 a.m. ( Toronto ... has been changed from that previous disclosed. The Meeting ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Now Has Four Phase 2 Trials Underway, MONTVALE, ... ) has dosed the first patient in a 160-patient ... failure. BREAK (Beginning a,Randomized Evaluation of the A.G.E. [Advanced ... a randomized,double-blind, placebo controlled study to assess the effect ...
... NEW YORK, May 13 NeoStem, Inc. (Amex: ... and long-term,storage of adult stem cells for future medical ... a new stem cell collection center in Coral,Gables, Florida, ... NeoStem,s Chairman and Chief Executive Officer,commented: "Securing the Florida ...
... 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today ... 2 study of subcutaneously,administered LHRH antagonist cetrorelix ... has been accepted for publication in an,upcoming ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:3/17/2015)... DIEGO , March 17, 2015 ... emotion analytics software, today announced general availability of ... web service for the analysis of facial expressions. ... experience advertising, media content, products and services. It ... attention, engagement and sentiment - as derived from ...
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
(Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Tobacco smoking by pregnant women has long been ... adverse effects on the development of a fetus. ... outcomes, including low birth weight, sudden infant death syndrome, ... and nicotine use in offspring. Despite this extensive literature, ...
... to help fertilize crops, it is vital to understand the ... Burkholderia , for example, includes dangerous disease-causing pathogens one ... but also many species that are safe and important ... good and evil be told apart? Yes, UCLA life scientists ...
... - Scientists at A*STAR,s Institute of Molecular and Cell ... sequenced and analysed the genome of the elephant shark. ... human and other vertebrate genomes revealed why the skeleton ... The findings carry potential implications for human bone disease ...
Cached Biology News:Maternal stress hormones and maternal smoking increase daughter's risk of nicotine dependence 2UCLA life scientists, colleagues differentiate microbial good and evil 2UCLA life scientists, colleagues differentiate microbial good and evil 3Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 2Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 3
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Jak3 Antibody Ship: Hot Store: -20 C...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: